Overview

Open Label Study for the Evaluation of Tolerability of Five Dose Levels of Cand5

Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
To establish the tolerability and preliminary efficacy of Cand5 by a single intravitreal injection in patients with wet age-related macular degeneration.
Phase:
Phase 1
Details
Lead Sponsor:
OPKO Health, Inc.